BIS News and Press, ProShares UltraShort Nasdaq Biotechnology From 10/17/19

On a strict party line basis, the U.S. House of Representatives' Education and Labor Committee voted 27-21 backing Speaker Nancy Pelosi's drug pricing bill (H.R. 3). All 27 Dems voted in favor and all 21 GOP members voted against. More news on: Pfizer Inc., Merck & Co., Inc., Bristol...

A preliminary analysis from the nonpartisan Congressional Budget Office (CBO) found that House Speaker Nancy Pelosi's (D-CA 12th District) bill to lower drug prices would save Medicare $345B between 2023 and 2029 by allowing the Secretary of Health and Human Services to negotiated lower pr...

According to a new report from the nonprofit Institute for Clinical and Economic Review (ICER), AbbVie ( ABBV -0.6% ) and Roche ( OTCQX:RHHBY -1.6% ) were number one and two, respectively, in terms of the impact of their price increases on U.S. drug spending. More news on: AbbVie Inc...

In an interview with CNBC, Health Secretary Alex Azar revealed that the Trump administration is working on a plan that would allow the U.S. to import medicines from Canada, but offered no additional details as to how the plan would work. More news on: ProShares Trust - ProShares Ultra Na...

By a 19-9 vote, the Prescription Drug Pricing Reduction Act has advanced out of the Senate Finance Committee and will go before the full Senate this fall. The bill would cap out-of-pocket costs for medicines at $3,100 per year for Medicare beneficiaries beginning in 2022 and require drug m...

U.S. Senator Jeanne Shaheen (D-NH) has introduced a bipartisan bill , the Insulin Price Reduction Act, that she says will rein in skyrocketing costs of insulin while holding pharmacy benefit managers to account for their role in surging prices, adding that the cost of the most popular insul...

Major drug makers are under water nearing the close as skittish investors move the sidelines ahead of President Trump's plan to peg Medicare reimbursement to the lowest ex-U.S. prices from a select group of countries. More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Heal...

Biotechs and biopharma players are modestly in the green after a D.C. district court stopped a Trump administration initiative requiring drug makers to disclose list prices in television advertisements. More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & ...

Biopharma and biotech players are mostly in the red (again) ahead of an expected executive order from President Trump aimed at corralling U.S. drug prices. Specifically, the order will contain a "favored nation" clause that will be the basis for Medicare reimbursement, i.e., the reimbursem...

Early July is typically one of the two times each calendar year that U.S. drugmakers hike prices. Yesterday, on cue, many appeared to do just that . More news on: GlaxoSmithKline plc, Amneal Pharmaceuticals, Inc., ProShares Ultra Nasdaq Biotechnology ETF, Healthcare stocks news, Stocks on...